[VIEW] agent=Patient Safety & Quality Director | scenario_id=115 | rounds=20

--- Round 0 ---
[R0.1] Patient Safety & Quality Director (speak, public): Let's start by discussing the recent FDA Class I recall affecting our IVP-500 infusion pumps. We need to understand the scale of affected devices and our operational capacity to execute the required mitigations.
[R0.2] Biomedical Engineering Manager (speak, public): We have 612 IVP-500 pumps in service across our facilities, with 410 of them located in our inpatient campuses. Our preventive maintenance is slightly overdue for 6% of the devices as of March 1st, 2026. We've also verified the failure mode through bench testing, showing an occlusion alarm delay of 18 seconds. The vendor has provided a remediation option in the form of a firmware patch, version 3.2.1, which takes about 12 minutes to install per pump. The average age of our IVP-500 pumps is 5.4 years.
[R0.3] Supply Chain & Procurement Director (speak, public): Thank you for the detailed information. From a procurement perspective, I can share that we have a replacement purchase option available with a trade-in program for $2,450 per pump if we trade in our old IVP-700 models. The standard lead time for new pumps is 8 weeks. We also have the option to add an extended warranty for $180 per pump-year. Additionally, the vendor is offering a recall credit of $900 per returned pump. We currently have 34 spare pumps in our central depot. Can you help me understand the patient-risk urgency associated with the recall and whether there are any undisclosed device-condition or regulatory escalation signals that we should be aware of?

--- Round 1 ---
[R1.1] Patient Safety & Quality Director (speak, public): We've had 4 infusion interruptions in the past 60 days across our system, primarily in high-risk units like our 58-bed ICU where pump competency training completion is at 72%. The manufacturer is requiring us to implement an updated clamp protocol within 7 days, and we need to notify the state about the adverse event within 24 hours. I'd like to understand better how these timelines align with our procurement and maintenance capabilities.
[R1.2] Biomedical Engineering Manager (speak, public): To address the urgency, we've verified that we have 34 spare pumps available in our central depot, which was shared by Supply Chain & Procurement Director. I need to understand the clinical mitigation expectations better - are there specific actions we need to take beyond the firmware patch and updated clamp protocol? Additionally, are there any severe escalation indicators or tight spending controls that we should be aware of when planning our response?
[R1.3] Supply Chain & Procurement Director (speak, public): To summarize, we have a clear picture of our IVP-500 pump deployment, the remediation available through a firmware patch, and the procurement options available to us. We've had 4 infusion interruptions in the past 60 days, and the manufacturer is requiring an updated clamp protocol within 7 days. From a procurement perspective, we can replace the pumps at $2,450 each with an 8-week lead time, and we have 34 spares. I believe we have enough information to make a decision on our response. I recommend we proceed with both the firmware patch installation and planning for accelerated device replacement, leveraging our available spares and the procurement options. Let's discuss the final recommendation.

--- Round 2 ---
[R2.1] Patient Safety & Quality Director (speak, public): I agree with your summary and recommendation. To finalize our response strategy, I'd like to confirm that we will proceed with the firmware patch installation within the manufacturer's required timeline and simultaneously plan for accelerated device replacement. Let's ensure that our clinical teams are aware of the updated clamp protocol and that we monitor the situation closely for any further escalation signals.
[R2.2] Biomedical Engineering Manager (leave, public): 
[R2.3] Supply Chain & Procurement Director (leave, public): 

--- Round 3 ---
[R3.1] Patient Safety & Quality Director (leave, public): 
[R3.2] Biomedical Engineering Manager (leave, public): 
[R3.3] Supply Chain & Procurement Director (leave, public): 

--- Round 4 ---
[R4.1] Patient Safety & Quality Director (leave, public): 
[R4.2] Biomedical Engineering Manager (leave, public): 
[R4.3] Supply Chain & Procurement Director (leave, public): 

--- Round 5 ---
[R5.1] Patient Safety & Quality Director (leave, public): 
[R5.2] Biomedical Engineering Manager (leave, public): 
[R5.3] Supply Chain & Procurement Director (leave, public): 

--- Round 6 ---
[R6.1] Patient Safety & Quality Director (leave, public): 
[R6.2] Biomedical Engineering Manager (leave, public): 
[R6.3] Supply Chain & Procurement Director (leave, public): 

--- Round 7 ---
[R7.1] Patient Safety & Quality Director (leave, public): 
[R7.2] Biomedical Engineering Manager (leave, public): 
[R7.3] Supply Chain & Procurement Director (leave, public): 

--- Round 8 ---
[R8.1] Patient Safety & Quality Director (leave, public): 
[R8.2] Biomedical Engineering Manager (leave, public): 
[R8.3] Supply Chain & Procurement Director (leave, public): 

--- Round 9 ---
[R9.1] Patient Safety & Quality Director (leave, public): 
[R9.2] Biomedical Engineering Manager (leave, public): 
[R9.3] Supply Chain & Procurement Director (leave, public): 

--- Round 10 ---
[R10.1] Patient Safety & Quality Director (leave, public): 
[R10.2] Biomedical Engineering Manager (leave, public): 
[R10.3] Supply Chain & Procurement Director (leave, public): 

--- Round 11 ---
[R11.1] Patient Safety & Quality Director (leave, public): 
[R11.2] Biomedical Engineering Manager (leave, public): 
[R11.3] Supply Chain & Procurement Director (leave, public): 

--- Round 12 ---
[R12.1] Patient Safety & Quality Director (leave, public): 
[R12.2] Biomedical Engineering Manager (leave, public): 
[R12.3] Supply Chain & Procurement Director (leave, public): 

--- Round 13 ---
[R13.1] Patient Safety & Quality Director (leave, public): 
[R13.2] Biomedical Engineering Manager (leave, public): 
[R13.3] Supply Chain & Procurement Director (leave, public): 

--- Round 14 ---
[R14.1] Patient Safety & Quality Director (leave, public): 
[R14.2] Biomedical Engineering Manager (leave, public): 
[R14.3] Supply Chain & Procurement Director (leave, public): 

--- Round 15 ---
[R15.1] Patient Safety & Quality Director (leave, public): 
[R15.2] Biomedical Engineering Manager (leave, public): 
[R15.3] Supply Chain & Procurement Director (leave, public): 

--- Round 16 ---
[R16.1] Patient Safety & Quality Director (leave, public): 
[R16.2] Biomedical Engineering Manager (leave, public): 
[R16.3] Supply Chain & Procurement Director (leave, public): 

--- Round 17 ---
[R17.1] Patient Safety & Quality Director (leave, public): 
[R17.2] Biomedical Engineering Manager (leave, public): 
[R17.3] Supply Chain & Procurement Director (leave, public): 

--- Round 18 ---
[R18.1] Patient Safety & Quality Director (leave, public): 
[R18.2] Biomedical Engineering Manager (leave, public): 
[R18.3] Supply Chain & Procurement Director (leave, public): 

--- Round 19 ---
[R19.1] Patient Safety & Quality Director (leave, public): 
[R19.2] Biomedical Engineering Manager (leave, public): 
[R19.3] Supply Chain & Procurement Director (leave, public): 

